Ikaria Overview

  • Founded

  • 2005

Founded
  • Status

  • Acquired/​Merged

  • Employees

  • 530

Employees
  • Latest Deal Type

  • M&A

  • Financing Rounds

  • 8

  • Investments

  • 1

Ikaria General Information

Description

Operator of an integrated critical care company intended to offer advanced critical care services. The company's critical care services focusses on developing and commercializing innovative therapies enabling to meet the unique and complex medical needs of critically ill patients.

Contact Information

Website
www.ikaria.com
Formerly Known As
ITL Holdings
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Hospitals/Inpatient Services
Other Industries
Biotechnology
Other Healthcare Services
Acquirer
Mallinckrodt
Primary Office
  • Perryville III Corporate Park, 53 Frontage Road, Third Floor
  • P.O. Box 9001
  • Hampton, NJ 08827
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ikaria Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ikaria‘s full profile, request access.

Request a free trial

Ikaria Patents

  • 14

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Ikaria Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20180066298-A1 Functionally modified polypeptides and radiobiosynthesis Pending 02-Sep-2016 000000000
US-20170049809-A1 Compositions and methods to modulate angiogenesis Abandoned 15-Jun-2007 000000000 0
US-20140220161-A1 Compositions and methods to modulate angiogenesis Abandoned 15-Jun-2007 000000000 0
US-20100247680-A1 Compositions and methods to modulate angiogenesis Abandoned 15-Jun-2007 000000000 0
JP-2010530001-A Compositions containing sulfides alone or in combination with nitric oxide and uses thereof Pending 15-Jun-2007 A61K33/04
To view Ikaria’s complete patent history, request access »

Ikaria Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ikaria Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ikaria‘s full profile, request access.

Request a free trial

Ikaria Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 000000000 28-Mar-2007 0000000000 00000 Pharmaceuticals
To view Ikaria’s complete investments history, request access »